Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Duac™Once Daily Gel
DuacOnce Daily · 1 trial · 1 indication
The assessor performed a count of inflammatory lesions (IL) (papules, pustules, nodules, and cysts), non-inflammatory lesions (NIL) (open and closed comedones) and total lesions (the sum of IL and NIL) at each study visit. Lesion counts were confined to the face. Change from Baseline at Week 12 was calculated as the value at Week 12 minus the value at Baseline. Parameters were estimated using analysis of covariance (ANCOVA) with treatment, center, treatment-by-centre interaction and Baseline lesion count in the model. Missing values were imputed using the last observation carried forward (LOCF), i.e., the last available observation was used to estimate subsequent missing data.
ISGA success is defined as the improvement of 2 grades or more in the participant's acne severity scale at Week 12. Acne severity of the participants' face was assessed by the assessor using the ISGA scale, ranging from 0 to 4: 0=clear skin with no ILs or NILs; 1=almost clear: rare NIL with no more than one small IL; 2=mild, some NILs with no more than a few ILs (papules/pustules only, no nodular lesions \[NLs\]); 3=moderate, up to many NILs and may have some ILs, but no more than one small NL; 4=severe: up to many NILs and ILs, but no more than a few NLs. Missing values were imputed using the LOCF, i.e., the last available observation was used to estimate subsequent missing data.
| Arm | Type | Description |
|---|---|---|
| Duac™Once Daily Gel | EXPERIMENTAL | Subjects will use Duac™Once Daily Gel (once daily in the evening)for 12 weeks. The subjects will be evaluated for change in lesion counts, ISGA, SGA , local tolerability, and AEs/SAEs at Weeks0, 1, 2, 4, 8, and 12 (or at early withdrawal). In addition, quality of life measures will be performed at every study visit |
| 1% clindamycin phosphate gel | ACTIVE_COMPARATOR | Subjects will use 1% clinidamycin phosphate gel (twice daily in the morning and evening)for 12 weeks. The subjects will be evaluated for change in lesion counts, ISGA, SGA , local tolerability, and AEs/SAEs at Weeks0, 1, 2, 4, 8, and 12 (or at early withdrawal). In addition, quality of life measures will be performed at every study visit |
| Name | Type | Description |
|---|---|---|
| Duac™Once Daily Gel | DRUG | 1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide |
| 1% clindamycin phosphate gel | DRUG | 1% clindamycin as clindamycin phosphate |
Inclusion Criteria: 1. Male and female subjects between 12 and 45 years of age, inclusive age will be calculated by date of birth, from 0 at birth. 2. Subjects who have: i. A minimum of 17 but not more than 60 facial inflammatory lesions (papules plus pustules), and no more than 1 facial nodula...
DuacOnce Daily is a dermatology treatment being developed for acne vulgaris, specifically mild to moderate acne. It is a small molecule therapy studied in a Phase 3 trial in China that enrolled 1,018 participants aged 12 years and older. It is not yet approved and remains in clinical development.
DuacOnce Daily is developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the Phase 3 clinical program evaluating the therapy in acne vulgaris.
DuacOnce Daily is in Phase 3 development. One Phase 3 trial has been completed, and no trials are currently active. The program has not been approved for marketing, so DuacOnce Daily remains an investigational therapy for acne vulgaris.
DuacOnce Daily has been studied in one completed Phase 3 trial, NCT01915732, titled a study of efficacy and safety of Duac compared with clindamycin phosphate gel in mild to moderate acne vulgaris. The trial enrolled 1,018 participants in China, was randomized and active-controlled, and included participants aged 12 years and older.
Yes, DuacOnce Daily is also known as DuacOnce Daily Gel. Both names refer to the same GSK small molecule product being developed for acne vulgaris, so searches for either name point to the same Phase 3 asset.